Cameco (CCJ) Declines More Than Market: Some Information for Investors

Cameco (CCJ) recently closed at $104.72, down 1.83% and trailing the broader market, despite a robust 27.76% gain over the past month. The uranium producer is slated to report earnings on November 5, 2025, with analysts projecting a significant quarterly EPS increase of 2,400% to $0.23, alongside full-year estimates of $1.15 EPS (+134.69%) and $2.54 billion revenue (+11.32%), supported by a 1.18% rise in consensus EPS estimates over 30 days. However, CCJ trades at a substantial forward P/E of 93.03, significantly above its industry average of 19.59, and currently holds a Zacks Rank #3 (Hold).

Analysis

Cameco (CCJ) recently closed at $104.72, experiencing a daily decline of 1.83%, which underperformed the S&P 500's 0.99% loss. Despite this, the stock has demonstrated significant momentum over the past month, rising 27.76% and notably outpacing the S&P 500's 3.59% gain and the Basic Materials sector's 5.52% loss. This recent performance highlights strong investor interest in the uranium producer.

The company is slated to report earnings on November 5, 2025, with robust projections. Upcoming quarterly EPS is forecast at $0.23, representing a substantial 2,400.00% year-over-year increase. Full-year Zacks Consensus Estimates further project EPS of $1.15 (+134.69%) and revenue of $2.54 billion (+11.32%), indicating strong fundamental growth.

Analyst sentiment appears positive, with the Zacks Consensus EPS estimate increasing by 1.18% over the last 30 days, although CCJ currently holds a Zacks Rank #3 (Hold). A key consideration is valuation, as Cameco trades at a Forward P/E of 93.03, significantly above its industry average of 19.59, suggesting a substantial premium. However, its industry, Mining - Miscellaneous, ranks in the top 25% of all industries, historically indicating outperformance.

Key Decisions for Investors

• Investors should closely monitor Cameco's upcoming earnings release on November 5, 2025, to validate the projected substantial EPS and revenue growth.
• Evaluate whether the current premium valuation, reflected by a 93.03 Forward P/E compared to the industry's 19.59, is justified by the company's long-term growth prospects and the positive industry outlook.
• Consider the implications of recent positive analyst estimate revisions and the strong industry rank for the uranium sector, which could support continued investor interest despite the high valuation.